Stock futures pointed to a little-changed open on Tuesday as the corporate earnings season picked up steam. The Dow Jones Industrial Average was headed for a flat open. S&P 500 futures also pointed to a muted start to the session. Dow components United Technologies and Procter & Gamble reported better-than-expected earnings before the bell, sending their shares higher by at least 1.6%. However, McDonald's shares dropped more than 3% after the fast-food giant posted weaker-than-forecast results.
Chinese Foreign Vice Minister Le Yucheng said Tuesday that China and the U.S. had made some progress on trade talks, noting any lingering problems could be solved as long as both countries showed respect to one another. "What China wants is to deliver a better life for the Chinese people," Le said. "We don't want to take anything from anyone else." President Donald Trump said earlier this month that both sides reached agreement on phase one of a broader trade deal. Chinese Vice Premier Liu He also said over the weekend that "substantial progress" had been made on trade. Investors are anxiously awaiting the resolution of the trade talks. The conflict, which has dragged on for more than a year, has dampened the outlook for corporate earnings and economic growth.
In the U.K., investors are bracing for two crucial votes on Brexit as Prime Minister Boris Johnson hopes to get enough parliamentary support for his European Union divorce bill. The first vote will be on a bill showing how Brexit would take place, which Johnson is expected to win. The second vote will determine whether Johnson can push through his plan for a vote before the end of Thursday. These votes come after U.K. lawmakers delayed a Brexit vote over the weekend, forcing Johnson to ask the EU for a deadline extension.
Sources told CNBC that SoftBank is in advanced talks to take over WeWork. SoftBank plans to spend between $4 billion and $5 billion for the embattled workspace company, sources said, a far cry from some of WeWork's earlier valuations. This move would bring SoftBank's stake in WeWork to more than 70% of the company.
Biogen shares jumped more than 30% in the premarket after the drug maker said it plans to seek regulatory approval for aducanumab, an Alzheimer's treatment. The company said its clinical trial of the treatment showed promise. Biogen shares are down sharply this year, losing more than a quarter of their value before Tuesday's increase. Earlier in 2019, Biogen ended two-stage trials of the treatment after an earlier analysis showed low chances of success.